NOT FOR DISTRIBUTION
Header cover image

Market Cap

kr.145.4b

Last Updated

2021/05/05 17:16 UTC

Data Sources

Company Financials +

Executive Summary

Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. More Details


Snowflake Analysis

Outstanding track record with flawless balance sheet.


Similar Companies

Share Price & News

How has Genmab's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: GMAB is not significantly more volatile than the rest of Danish stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: GMAB's weekly volatility (4%) has been stable over the past year.


Market Performance


7 Day Return

-2.2%

GMAB

-2.1%

DK Biotechs

-0.4%

DK Market


1 Year Return

29.4%

GMAB

27.1%

DK Biotechs

33.6%

DK Market

Return vs Industry: GMAB exceeded the Danish Biotechs industry which returned 28.3% over the past year.

Return vs Market: GMAB underperformed the Danish Market which returned 32.9% over the past year.


Shareholder returns

GMABIndustryMarket
7 Day-2.2%-2.1%-0.4%
30 Day6.5%4.7%4.3%
90 Day-10.6%-8.4%4.0%
1 Year29.4%29.4%27.2%27.1%37.1%33.6%
3 Year78.7%78.7%78.6%74.1%60.6%48.2%
5 Year122.3%122.3%52.7%46.4%81.9%58.0%

Long-Term Price Volatility Vs. Market

How volatile is Genmab's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Genmab undervalued compared to its fair value and its price relative to the market?

38.0%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: GMAB (DKK2223) is trading below our estimate of fair value (DKK3583.89)

Significantly Below Fair Value: GMAB is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: GMAB is poor value based on its PE Ratio (30.5x) compared to the XE Biotechs industry average (28x).

PE vs Market: GMAB is poor value based on its PE Ratio (30.5x) compared to the Danish market (17.1x).


Price to Earnings Growth Ratio

PEG Ratio: GMAB is poor value based on its PEG Ratio (2x)


Price to Book Ratio

PB vs Industry: GMAB is overvalued based on its PB Ratio (7.6x) compared to the DK Biotechs industry average (6.3x).


Future Growth

How is Genmab forecast to perform in the next 1 to 3 years based on estimates from 21 analysts?

15.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: GMAB's forecast earnings growth (15.2% per year) is above the savings rate (0.1%).

Earnings vs Market: GMAB's earnings (15.2% per year) are forecast to grow faster than the Danish market (10.9% per year).

High Growth Earnings: GMAB's earnings are forecast to grow, but not significantly.

Revenue vs Market: GMAB's revenue (13.9% per year) is forecast to grow faster than the Danish market (6.9% per year).

High Growth Revenue: GMAB's revenue (13.9% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: GMAB's Return on Equity is forecast to be high in 3 years time (20.3%)


Past Performance

How has Genmab performed over the past 5 years?

40.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: GMAB has high quality earnings.

Growing Profit Margin: GMAB's current net profit margins (47.1%) are higher than last year (40.4%).


Past Earnings Growth Analysis

Earnings Trend: GMAB's earnings have grown significantly by 40.9% per year over the past 5 years.

Accelerating Growth: GMAB's earnings growth over the past year (119.4%) exceeds its 5-year average (40.9% per year).

Earnings vs Industry: GMAB earnings growth over the past year (119.4%) exceeded the Biotechs industry 21.8%.


Return on Equity

High ROE: GMAB's Return on Equity (24.9%) is considered high.


Financial Health

How is Genmab's financial position?


Financial Position Analysis

Short Term Liabilities: GMAB's short term assets (DKK18.8B) exceed its short term liabilities (DKK1.3B).

Long Term Liabilities: GMAB's short term assets (DKK18.8B) exceed its long term liabilities (DKK769.0M).


Debt to Equity History and Analysis

Debt Level: GMAB is debt free.

Reducing Debt: GMAB has not had any debt for past 5 years.

Debt Coverage: GMAB has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: GMAB has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is Genmab current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate GMAB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate GMAB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if GMAB's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if GMAB's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of GMAB's dividend in 3 years as they are not forecast to pay a notable one for the Danish market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.2yrs

Average management tenure


CEO

Jan van de Winkel (59 yo)

10.92yrs

Tenure

kr.35,200,000

Compensation

Dr. Jan G. J. van de Winkel, Ph.D., serves as a Member of Advisory board at Thuja Capital Management B.V. Dr. van de Winkel served as a Member of Scientific Advisory Board. He is a Co-Founder of Genmab A/S...


CEO Compensation Analysis

Compensation vs Market: Jan's total compensation ($USD5.68M) is above average for companies of similar size in the Danish market ($USD3.69M).

Compensation vs Earnings: Jan's compensation has increased by more than 20% in the past year.


Leadership Team

Experienced Management: GMAB's management team is considered experienced (2.2 years average tenure).


Board Members

Experienced Board: GMAB's board of directors are not considered experienced ( 2.2 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Genmab A/S's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Genmab A/S
  • Ticker: GMAB
  • Exchange: CPSE
  • Founded: 1999
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: kr.145.416b
  • Shares outstanding: 65.36m
  • Website: https://www.genmab.com

Number of Employees


Location

  • Genmab A/S
  • Kalvebod Brygge 43
  • Copenhagen
  • Capital Region of Denmark
  • 1560
  • Denmark

Listings


Biography

Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the tr...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/05/05 17:16
End of Day Share Price2021/05/05 00:00
Earnings2020/12/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.